Calciscon

Calciscon is a pioneering company specializing in the development of diagnostic methods to measure Calciprotein Particles (CPP), which are significant drivers of inflammation in chronic diseases. Founded in 2013 by Dr. Andreas Pasch, the company emerged from groundbreaking research in renal medicine aimed at understanding rapid blood vessel calcification in kidney patients. Calciscon's flagship product, the T50 blood test, is the first functional test designed to assess Calcification Propensity, identifying patients with high cardiovascular risk and offering the potential to slow disease progression. The company serves patients primarily through accredited medical laboratories, focusing on those undergoing dialysis who are at exceptional risk for accelerated vascular calcifications. Operating in the medical diagnostics market, Calciscon generates revenue by providing its CE-marked T50 test to healthcare providers. The T50 test offers a comprehensive functional assessment of a patient's humoral calcification system, providing real-time insights and future outlooks on calcification propensity, unlike traditional methods such as X-rays or CT scans that only report past calcification events.

Keywords: Calciprotein Particles, diagnostics, chronic diseases, T50 blood test, cardiovascular risk, renal medicine, dialysis, vascular calcifications, humoral calcification system, medical laboratories.